116 related articles for article (PubMed ID: 20429730)
21. Farnesol inhibits tumor growth and enhances the anticancer effects of bortezomib in multiple myeloma xenograft mouse model through the modulation of STAT3 signaling pathway.
Lee JH; Kim C; Kim SH; Sethi G; Ahn KS
Cancer Lett; 2015 May; 360(2):280-93. PubMed ID: 25697480
[TBL] [Abstract][Full Text] [Related]
22. Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation.
Morikawa Y; Koike H; Sekine Y; Matsui H; Shibata Y; Ito K; Suzuki K
Biochem Biophys Res Commun; 2012 Mar; 419(3):584-9. PubMed ID: 22387542
[TBL] [Abstract][Full Text] [Related]
23. Novel combination of docetaxel and thymoquinone induces synergistic cytotoxicity and apoptosis in DU-145 human prostate cancer cells by modulating PI3K-AKT pathway.
Dirican A; Atmaca H; Bozkurt E; Erten C; Karaca B; Uslu R
Clin Transl Oncol; 2015 Feb; 17(2):145-51. PubMed ID: 25060568
[TBL] [Abstract][Full Text] [Related]
24. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway.
Virtanen SS; Väänänen HK; Härkönen PL; Lakkakorpi PT
Cancer Res; 2002 May; 62(9):2708-14. PubMed ID: 11980672
[TBL] [Abstract][Full Text] [Related]
25. Pamidronate inhibits antiapoptotic bcl-2 expression through inhibition of the mevalonate pathway in prostate cancer PC-3 cells.
Iguchi K; Tatsuda Y; Usui S; Hirano K
Eur J Pharmacol; 2010 Sep; 641(1):35-40. PubMed ID: 20519142
[TBL] [Abstract][Full Text] [Related]
26. The disintegrin contortrostatin in combination with docetaxel is a potent inhibitor of prostate cancer in vitro and in vivo.
Lin E; Wang Q; Swenson S; Jadvar H; Groshen S; Ye W; Markland FS; Pinski J
Prostate; 2010 Sep; 70(12):1359-70. PubMed ID: 20623636
[TBL] [Abstract][Full Text] [Related]
27. Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid.
Vogt U; Bielawski KP; Bosse U; Schlotter CM
Oncol Rep; 2004 Nov; 12(5):1109-14. PubMed ID: 15492801
[TBL] [Abstract][Full Text] [Related]
28. Farnesol production from Escherichia coli by harnessing the exogenous mevalonate pathway.
Wang C; Yoon SH; Shah AA; Chung YR; Kim JY; Choi ES; Keasling JD; Kim SW
Biotechnol Bioeng; 2010 Oct; 107(3):421-9. PubMed ID: 20552672
[TBL] [Abstract][Full Text] [Related]
29. Sequence- and concentration-dependent effects of acute and long-term exposure to the bisphosphonate ibandronate in combination with single and multiple fractions of ionising radiation doses in human breast cancer cell lines.
Journé F; Magné N; Chaboteaux C; Kinnaert E; Bauss F; Body JJ
Clin Exp Metastasis; 2006; 23(2):135-47. PubMed ID: 16912915
[TBL] [Abstract][Full Text] [Related]
30. Evidence of a novel docetaxel sensitizer, garlic-derived S-allylmercaptocysteine, as a treatment option for hormone refractory prostate cancer.
Howard EW; Lee DT; Chiu YT; Chua CW; Wang X; Wong YC
Int J Cancer; 2008 May; 122(9):1941-8. PubMed ID: 18183597
[TBL] [Abstract][Full Text] [Related]
31. Knockdown of p21-activated kinase 6 inhibits prostate cancer growth and enhances chemosensitivity to docetaxel.
Wen X; Li X; Liao B; Liu Y; Wu J; Yuan X; Ouyang B; Sun Q; Gao X
Urology; 2009 Jun; 73(6):1407-11. PubMed ID: 19362342
[TBL] [Abstract][Full Text] [Related]
32. Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models.
Van Laar ES; Weitman S; MacDonald JR; Waters SJ
Prostate; 2004 Apr; 59(1):22-32. PubMed ID: 14991863
[TBL] [Abstract][Full Text] [Related]
33. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines.
Bae SH; Ryoo HM; Kim MK; Lee KH; Sin JI; Hyun MS
Oncol Rep; 2008 Apr; 19(4):1027-32. PubMed ID: 18357392
[TBL] [Abstract][Full Text] [Related]
34. Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment.
Brubaker KD; Brown LG; Vessella RL; Corey E
BMC Cancer; 2006 Jan; 6():15. PubMed ID: 16417633
[TBL] [Abstract][Full Text] [Related]
35. In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines.
Dasmahapatra GP; Didolkar P; Alley MC; Ghosh S; Sausville EA; Roy KK
Clin Cancer Res; 2004 Aug; 10(15):5242-52. PubMed ID: 15297428
[TBL] [Abstract][Full Text] [Related]
36. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
[TBL] [Abstract][Full Text] [Related]
37. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells.
Oades GM; Senaratne SG; Clarke IA; Kirby RS; Colston KW
J Urol; 2003 Jul; 170(1):246-52. PubMed ID: 12796698
[TBL] [Abstract][Full Text] [Related]
38. Additive/synergistic anti-tumoral effects of the combination of docetaxel and zoledronic acid on prostate cancer cells: possible mechanisms?
Ural AU; Avcu F
Acta Oncol; 2006; 45(4):491-2. PubMed ID: 16760189
[No Abstract] [Full Text] [Related]
39. Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone refractory prostate cancer cells.
Hwang JJ; Kim YS; Kim MJ; Kim DE; Jeong IG; Kim CS
J Urol; 2010 Dec; 184(6):2557-64. PubMed ID: 21030039
[TBL] [Abstract][Full Text] [Related]
40. Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro.
Budman DR; Calabro A; Kreis W
Anticancer Drugs; 2002 Nov; 13(10):1011-6. PubMed ID: 12439335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
